Clearmind Medicine (CMND) Non Operating Income (2022 - 2026)
Clearmind Medicine (CMND) posted quarterly Non Operating Income of -$473133.0 for Q2 2026, down 187.02% year-over-year from $543711.0 in Q2 2025, and down 148.09% quarter-over-quarter from -$190708.0 in Q1 2026.
Clearmind Medicine (CMND) Non Operating Income (2022 - 2026) Analysis & Trends
Clearmind Medicine's Non Operating Income history runs 5 years deep, the most recent figure standing at -$473133.0 for Q2 2026.
- In Q2 2026, Non Operating Income fell 187.02% year-over-year to -$473133.0; the TTM figure through Apr 2026 stood at $209199.0 (down 82.94% YoY), while the FY2025 annual figure was $1.9 million, up 116.61% from the prior year.
- Non Operating Income for Q2 2026 stood at -$473133.0, down from -$190708.0 in the prior quarter.
- The five-year high for Non Operating Income was $798557.0 in Q4 2024, with the low at -$2.3 million in Q4 2023.
- The 5-year median for Non Operating Income is -$42345.0 (2022), against an average of -$40402.6.
- Peak annual rise in Non Operating Income reached 494.33% in 2023, while the deepest fall reached 1458.29% in 2023.
- Clearmind Medicine's Non Operating Income stood at -$382686.0 in 2022, then plunged by 513.29% to -$2.3 million in 2023, then jumped by 134.03% to $798557.0 in 2024, then declined by 3.5% to $770610.0 in 2025, then plunged by 161.4% to -$473133.0 in 2026.
- Business Quant data shows CMND's Non Operating Income at -$473133.0 in Q2 2026, -$190708.0 in Q1 2026, and $770610.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Clearmind Medicine | 520,887.91 | -13.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -473,133.00 |
| Jan 31, 2026 | -190,708.00 |
| Oct 31, 2025 | 770,610.00 |
| Jul 31, 2025 | 102,430.00 |
| Apr 30, 2025 | 543,711.00 |
| Jan 31, 2025 | 463,888.00 |
| Oct 31, 2024 | 798,557.00 |
| Jul 31, 2024 | -580,079.00 |
| Apr 30, 2024 | 432,044.00 |
| Jan 31, 2024 | 217,691.00 |
| Oct 31, 2023 | -2.35 Mn |
| Jul 31, 2023 | 521,061.00 |
| Apr 30, 2023 | -303,821.64 |
| Jan 31, 2023 | -79,583.00 |
| Oct 31, 2022 | -382,686.00 |
| Jul 31, 2022 | -132,137.00 |
| Apr 30, 2022 | -83,018.56 |
| Jan 31, 2022 | -5,107.09 |